QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
Log in
NYSEMKT:PHGE

BiomX Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume25,236 shs
Market Capitalization$152.50 million
P/E RatioN/A
Dividend YieldN/A
Beta0.48
BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEMKT:PHGE
CUSIPN/A
CIKN/A
Phone972 7 23942377
Employees73
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.83 per share

Profitability

Net Income$-20,560,000.00

Miscellaneous

Market Cap$152.50 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.56 out of 5 stars

Medical Sector

1393rd out of 1,958 stocks

Biological Products, Except Diagnostic Industry

156th out of 177 stocks

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
30 days | 90 days | 365 days | Advanced Chart

Receive PHGE News and Ratings via Email

Sign-up to receive the latest news and ratings for PHGE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BiomX (NYSEMKT:PHGE) Frequently Asked Questions

Is BiomX a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BiomX in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BiomX stock.
View analyst ratings for BiomX
or view top-rated stocks.

What stocks does MarketBeat like better than BiomX?

Wall Street analysts have given BiomX a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BiomX wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are BiomX's key executives?

BiomX's management team includes the following people:
  • Mr. Jonathan Eitan Solomon MBA, CEO & Director (Age 44, Pay $615.4k)
  • Mr. Assaf Oron, Chief Bus. Officer (Age 47, Pay $346.83k)
  • Dr. Sailaja Puttagunta, Chief Medical Officer (Age 52, Pay $495.8k)
  • Prof. Rotem Sorek Ph.D., Scientific Founder
  • Dr. Eran Elinav, Scientific Founder
  • Prof. Timothy K. Lu, Scientific Founder
  • Ms. Marina Wolfson, Sr. VP of Fin. & Operations (Age 37)
  • Noel Kurdi, VP of Investor Relations & Strategy
  • Ms. Inbal Benjamini-Elran, VP of HR
  • Dr. Merav Bassan Ph.D., Chief Devel. Officer (Age 55)

Who are some of BiomX's key competitors?

What other stocks do shareholders of BiomX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BiomX investors own include Abiomed (ABMD), Catalent (CTLT), Hologic (HOLX), Merck & Co., Inc. (MRK), Net Element (NETE), Novavax (NVAX), Quanterix (QTRX), ARCA biopharma (ABIO), AbbVie (ABBV) and AudioEye (AEYE).

What is BiomX's stock symbol?

BiomX trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "PHGE."

How do I buy shares of BiomX?

Shares of PHGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does BiomX make?

BiomX has a market capitalization of $0.00. The company earns $-20,560,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis.

How many employees does BiomX have?

BiomX employs 73 workers across the globe.

What is BiomX's official website?

The official website for BiomX is www.biomx.com.

Where are BiomX's headquarters?

BiomX is headquartered at 7 PINHAS SAPIR ST. FLOOR 2, NESS ZIONA L3, 7414002.

How can I contact BiomX?

BiomX's mailing address is 7 PINHAS SAPIR ST. FLOOR 2, NESS ZIONA L3, 7414002. The company can be reached via phone at 972 7 23942377 or via email at [email protected]


This page was last updated on 2/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.